Rodman & Renshaw analyst Seema Sheoran initiated coverage of SAB Biotherapeutics (SABS) with a Buy rating and $13 price target implying 235% upside from current share levels. SAB is focused on developing SAB-142, a potentially disease modifying immunotherapy for autoimmune type 1 diabetes, the analyst tells investors in a research note. The firm sees the data in the second half of 2027 as the key catalyst for the stock.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SABS:
- SABS Upcoming Earnings Report: What to Expect?
- SAB Biotherapeutics Launches Major Equity Financing Offering
- SAB Biotherapeutics 19.325M share Spot Secondary priced at $3.85
- SAB Biotherapeutics $75M Spot Secondary; price range $3.75-$4.07
- SAB Biotherapeutics announces common stock offering, no amount given